GLP-1 If You Have a Small Amount of Weight to Lose

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

Who actually qualifies for a GLP-1?

Situation	GLP-1 generally appropriate?	Why
BMI ≥ 30	Generally appropriate	Meets the FDA-approved threshold
BMI 27–29.9 + a weight-related condition	Generally appropriate	Meets the FDA-approved threshold with comorbidity
BMI 27–29.9, no condition	Generally not	Below threshold without a comorbidity
BMI under 27 / cosmetic 15–20 lbs	Generally not	Below the FDA-approved threshold

Eligibility is confirmed by a licensed clinician based on your individual evaluation. Thresholds apply to both semaglutide (Wegovy FDA prescribing label) and tirzepatide products. Information is current as of June 2026.

Why 15–20 pounds usually isn't enough to qualify

The FDA-approved thresholds for GLP-1 weight-management medications exist because these are powerful drugs with real side effects, a boxed warning, and a risk-benefit calculation calibrated for people with meaningful excess weight or weight-related disease. The NIDDK's guidance on prescription weight-loss medications is clear: these medications are indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or sleep apnea.

The pivotal clinical trials reinforced exactly these enrollment criteria. The STEP 1 trial (Wilding et al., NEJM 2021) — which studied semaglutide 2.4 mg in adults with obesity — enrolled participants with a BMI of 30 or higher, or 27 or higher with a weight-related condition. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) used the same enrollment criteria for tirzepatide. Those thresholds aren't arbitrary — they reflect the population in whom these medications demonstrated a meaningful clinical benefit that outweighed their risks. (Note: these are studies of the branded molecules, not of any compounded preparation.)

If your BMI is under 27 — or 27–29.9 with no weight-related condition — a GLP-1 generally isn't approved for you, and prescribing it anyway isn't responsible care.

Why a clinic that says "no" is a good sign

A provider willing to prescribe a GLP-1 regardless of your BMI — no real evaluation, anyone approved — is a red flag, not a convenience. Legitimate clinics screen for eligibility and decline applicants who don't meet the criteria. The FDA has specifically raised concerns about unapproved GLP-1 use for weight loss in people who don't meet clinical criteria. The same diligence that turns you away when you don't qualify protects you once you are a candidate.

Learn more about what to expect from the intake and evaluation process: How online GLP-1 programs work.

What to do if you don't qualify right now

If you're under the threshold, a clinician can discuss evidence-based alternatives — nutrition, movement, and behavioral support — and re-evaluate if your situation changes.

If you're close to the line (BMI 27–29.9), it's worth a proper evaluation: if you have high blood pressure, prediabetes, high cholesterol, or sleep apnea, you may qualify even without a BMI of 30. See getting a GLP-1 without a BMI of 30 for the full list of qualifying conditions. And if you're unsure whether you meet the threshold at all, start with the full eligibility guide.

Compounded GLP-1 medications — like all GLP-1 therapies — require a documented patient-specific clinical need, as the FDA's guidance on human drug compounding makes clear. Nouri clinicians follow the same standards.

How Nouri works for people who do qualify

Nouri is designed to be the legitimate, straightforward option for adults who meet the clinical criteria. You complete a 5-minute online questionnaire; a U.S.-licensed clinician reviews your file — a real evaluation, with a video visit where your state requires one — and, if appropriate, your medication ships discreetly from a named, state-licensed 503A pharmacy (Jungle Jim's Pharmacy, Fairfield, OH, or VialsRX). Nouri is LegitScript-certified, available in all 50 states, and includes a personalized nutrition plan and a movement plan in the program price.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans. Plans start at compounded semaglutide from $120/month and compounded tirzepatide from $175/month. Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

Related getting-started guides

• Do You Qualify for a GLP-1? (full eligibility guide)
• Can You Get a GLP-1 Without a BMI of 30?
• How Online GLP-1 Programs Work
• How to Get Semaglutide Online

Frequently asked questions

Can you take a GLP-1 for only 15–20 pounds?

Usually not. GLP-1s are FDA-approved for a BMI of 30+, or 27+ with a weight-related condition. If you only have 15–20 pounds to lose and your BMI is under 27, you generally don't qualify, and a responsible clinician won't prescribe one for cosmetic weight loss.

Can I get semaglutide if I'm not very overweight?

Only if your BMI is 27 or higher and you have a weight-related condition (like high blood pressure or sleep apnea), or your BMI is 30+. Below that, a GLP-1 generally isn't approved or appropriate.

Is Ozempic worth it for a little weight loss?

For someone below the approved BMI thresholds, the risks and cost generally aren't justified for minimal weight loss — and it's not an approved use. A clinician can suggest safer, evidence-based options for small amounts of weight.

Do you have to be obese to take a GLP-1?

Not necessarily — a BMI of 27–29.9 (overweight, not obese) can qualify if you have a weight-related condition. But you do need to meet a threshold; GLP-1s aren't approved for people well within a normal weight range.

Can I take Ozempic to lose 20 pounds?

If your BMI is under 27 (or 27–29.9 with no weight-related condition), a GLP-1 generally isn't approved or appropriate just to lose 20 pounds, and a responsible clinician won't prescribe it for that. Eligibility is based on BMI thresholds, not a pound target.

How much weight do you have to lose to qualify for a GLP-1?

Eligibility is based on BMI, not pounds: generally a BMI of 30+, or 27+ with a weight-related condition such as high blood pressure, type 2 diabetes, or sleep apnea. A clinician calculates your BMI from your height and weight and confirms eligibility.

Sources & references

• FDA: Concerns about unapproved GLP-1 drugs used for weight loss (Tier 1 — FDA)
• NIDDK: Prescription medications to treat overweight and obesity (Tier 1 — NIH/NIDDK)
• Wegovy (semaglutide) FDA prescribing label (Tier 1 — FDA)
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021 (STEP 1) (Tier 1 — NEJM)
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022 (SURMOUNT-1) (Tier 1 — NEJM)
• FDA: Human Drug Compounding (Tier 1 — FDA)
• FDA BeSafeRx: Buying medicine online safely (Tier 1 — FDA)

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — eligibility and prescribing decisions are made by a licensed clinician based on your individual evaluation. Ozempic®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Telehealth prescribing requirements vary by state and may change. Information is current as of June 2026.